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Abstract 
Background: Autoimmune Addison’s disease (AAD) is caused by multiple genetic and environmental factors. Vari-
ants of genes encoding immunologically important proteins such as the HLA molecules are strongly associated with 
AAD, but any environmental risk factors have yet to be defined. We hypothesized that primary or reactivating infec-
tions with cytomegalovirus (CMV) could represent an environmental risk factor in AAD, and that CMV specific CD8+ T 
cell responses may be dysregulated, possibly leading to a suboptimal control of CMV. In particular, the objective was 
to assess the HLA-B8 restricted CD8+ T cell response to CMV since this HLA class I variant is a genetic risk factor for 
AAD.
Methods: To examine the CD8+ T cell response in detail, we analyzed the HLA-A2 and HLA-B8 restricted responses in 
AAD patients and healthy controls seropositive for CMV antibodies using HLA multimer technology, IFN-γ ELISpot and 
a CD107a based degranulation assay.
Results: No differences between patients and controls were found in functions or frequencies of CMV-specific T 
cells, regardless if the analyses were performed ex vivo or after in vitro stimulation and expansion. However, individual 
patients showed signs of reactivating CMV infection correlating with poor CD8+ T cell responses to the virus, and a 
concomitant upregulation of interferon regulated genes in peripheral blood cells. Several recently diagnosed AAD 
patients also showed serological signs of ongoing primary CMV infection.
Conclusions: CMV infection does not appear to be a major environmental risk factor in AAD, but may represent a 
precipitating factor in individual patients.
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Background
Autoimmune Addison’s disease (AAD) is an organ-
specific autoimmune endocrinological disorder with 
uncertain pathogenesis caused by underlying environ-
mental and genetic factors [1, 2]. AAD is characterized 
by highly specific immune responses against adrenocor-
tical autoantigens, illustrated by autoantibodies against 
21-hydroxylase (21OH), an enzyme involved in steroid 
hormone biosynthesis [3]. The pathological significance 
of these autoantibodies are uncertain however, it is 
assumed instead that 21OH-specific autoreactive T cells 
are the major players of the molecular pathogenesis of 
AAD. Both CD8+ and CD4+ 21OH-specific T cells have 
recently been described [4–6]. While the genetic back-
ground of AAD has been extensively characterized dur-
ing the last decade, with numerous predisposing genetic 
variants discovered in genes encoding mostly immuno-
logically relevant proteins [2, 7], almost nothing is known 
about the environmental risk factors. Viruses and other 
microbial pathogens are major environmental candidates 
as the hormone producing cells of the adrenal cortex are 
permissive to a wide range of infections, many of which 
can be clinically silent [8, 9]. Common viral agents known 
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include herpes simplex 1 and 2, Epstein-Barr virus, ade-
novirus, hepatitis B and cytomegalovirus (CMV) [9]. 
However, their possible involvement in the induction of 
autoimmune adrenalitis, and eventually overt AAD, is 
unclear.
The human cytomegalovirus, a member of the her-
pesviridae family, is a ubiquitous pathogen that persis-
tently infects 60–90  % of the world’s population [10]. 
After a primary infection, which can be asymptomatic 
or cause a clinical picture resembling mononucleosis 
with fever, hepatitis, swollen lymph nodes and lympho-
penia, the virus resides in latently infected monocytes 
and premonocytic cells with periodical reactivation 
driven by inflammation (e.g. increased levels of TNFα) 
or immunosuppression (e.g. HIV/AIDS or transplanta-
tion) [11, 12]. Primary or reactivating infections with 
CMV may cause severe disease in immunodeficient indi-
viduals and infants, and occasionally also in individuals 
with seemingly well-preserved immunity. During active 
CMV infection patients often suffer from immunologi-
cal dysfunctions and autoimmune phenomena, such as 
autoantibodies [13–15]. In genetically predisposed indi-
viduals, primary CMV infections have been described as 
triggers of autoimmune disorders, such as vasculitides 
and scleroderma, which developed concomitantly with 
or immediately after active CMV infection in previously 
healthy, immunocompetent subjects [16–18]. Multiple 
case reports also describe primary, reactivating or persis-
tent CMV infections as possible triggers of autoimmune 
endocrine diseases such as type 1 diabetes (T1D), Graves’ 
disease and AAD [19–22]. Importantly, CMV is known 
to infect and cause cytopathic damage to the adrenal 
cortex, and may directly cause adrenal insufficiency in 
infants and in immunodeficient individuals [23–26].
Since cellular immunity to specific viral agents have not 
been investigated in patients with AAD, the objective was 
to characterize the CD8+ T cell responses against specific 
HLA class I epitopes of CMV. In particular we wanted 
to look at HLA-B8 restricted anti-CMV responses, since 
HLA-B8 is the predominant HLA class I allele associated 
with AAD [27, 28]. This could also help to unravel pos-
sible gene-environment interactions jointly influencing 
the risk of developing AAD. We also found it interest-
ing to investigate how a patient group with a dysregu-
lated immune system, such as patients with AAD, would 
respond to a common virus such as CMV.
Methods
Patients and controls
The patient material [serum and peripheral blood mon-
onuclear cells (PBMC)] used in the current study was 
accessed through the Norwegian registry and biobank 
for organ specific autoimmune diseases (ROAS). In 
total, 95 consecutively selected patients with confirmed 
AAD and known HLA-type (as described in [29]) were 
recruited. The control material was provided by the local 
blood bank and included 49 age- and gender-matched 
healthy controls. In addition, PBMC from 7 HLA-B8 
positive healthy controls with confirmed positive CMV 
serostatus were purchased from Cellular Technology, Ltd 
(Shaker Heights, OH, USA) and included in the study. All 
patients and controls signed informed consent approved 
by the Health Region West ethics committee (149/96-
47.96) and all experiments were conducted in accordance 
with the declaration of Helsinki. Heparinized blood sam-
ples were processed essentially as described previously 
[4]. In brief, plasma samples were isolated, aliquoted and 
kept frozen at −20  °C, while PBMC were isolated using 
Ficoll-Paque Plus (GE Healthcare, Little Chalfont, UK). 
The isolated PBMC were kept cryopreserved at −150 °C 
in 90  % human AB-serum (Lonza, Basel, Switzerland) 
and 10  % dimethylsulphoxide (DMSO) (Sigma-Aldrich, 
St Louis, MO, USA).
CMV peptides and MHC dextramer reagents
HLA-A2 and -B8 restricted peptides, NLVPMVATV 
(from the pp65 antigen) and QIKVRVDMV (from the IE1 
antigen), respectively, were purchased from Proimmune/
thinkpeptides (Oxford, UK). MHC dextramers consisting 
of recombinant HLA-A2 and HLA-B8 and loaded with 
their respective cognate CMV peptides were purchased 
from Immudex (Copenhagen, Denmark), along with 
negative control MHC dextramers loaded with HIV gag-
derived peptides SLYNTVATL (HLA-A2 restricted) and 
DIYKRWII (HLA-B8 restricted).
HLA typing of whole blood
The correct HLA type (HLA-A2 or HLA-B8) of the 
healthy controls collected from the blood bank needed 
to be confirmed for inclusion in the downstream assays 
and this was performed using flow cytometry. 10  µL of 
FITC-conjugated anti-human HLA-A2 (clone BB7.2, 
Biolegend, San Diego, CA, USA) or PE-conjugated anti-
human HLA-B8 antibodies (clone REA145, Miltenyi Bio-
tech, Bergisch Gladbach, Germany) was added to 100 µL 
heparinized whole blood and incubated on ice for 30 min 
in the dark. Next, 2 mL of 1× lysisbuffer (BD Pharm lyse, 
BD Biosciences, San Jose, CA, USA) were added to each 
tube for a 10 min incubation at RT. The cells were then 
centrifuged for 5 min at 400×g and re-suspended in 2 mL 
phosphate-buffered-saline (PBS) with 1  % (w/v) bovine 
serum albumin (BSA, Sigma-Aldrich). The centrifuga-
tion step was repeated and the cells were re-suspended 
in 250 µL PBS with 1 % BSA and kept on ice in the dark 
until analyzed on an Accuri C6 flow cytometer. The gat-
ing procedure is described in Additional file 1: Figure S1.
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Determination of IgG and IgM antibodies to CMV in human 
serum
Sera or plasma from the patients and healthy controls 
selected for this study were examined for IgG or IgM 
antibodies to CMV using PLATELIA CMV immunoas-
say from BioRad (Hercules, CA, USA) according to the 
manufacturer’s protocol. Patients with positive IgG were 
included in the downstream assays.
Cellular immune responses against CMV
Having determined the HLA type and CMV serostatus 
of our patients and controls, only those with antibodies 
to CMV and positive for either HLA-A2 (patients n = 6, 
controls n = 6) or –B8 (patients n = 9, controls n = 10) 
were selected for further investigation. Several differ-
ent experiments were performed based on the amount 
of cells available. At day 0 PBMC stored at −150  °C 
were thawed, washed and re-suspended in serum free 
AIM V medium (Life-technologies, Paisley, UK) sup-
plemented with 10 % human AB-Serum at 2 × 106 cells/
mL. 750  µL of the cell suspension was used for ex  vivo 
CMV dextramer analysis (see below), 1200 µL was used 
in an ex vivo ELISpot assay and the remaining cells were 
seeded at 2 ×  106 cells/mL in 24-well culture plates for 
in vitro expansion. After having rested the cells for 24 h, 
at day 1 they were supplemented with 20 U/mL of IL-2 
(Life-technologies) and stimulated with a final concen-
tration of 1 µg/mL of B8 or A2 specific CMV peptide. At 
day 4, 6, 8 and 11, 1 mL of growth media was removed 
from the cells and 1 mL fresh media was added. At day 
13 the cells were harvested and new dextramer and ELIS-
pot assays were performed in addition to a degranulation 
assay. All assays are described in details below.
CMV dextramer analysis
The 750  µL of 2  ×  106 cells/mL was divided between 
four tubes, three tubes with 167,000 cells and one tube 
with 1 ×  106 cells. 2  mL of wash buffer (PBS with 5  % 
FBS (Life-technologies)) were added to each tube and 
centrifuged at 300×g for 5  min. The cells were re-sus-
pended in 50  µL wash buffer and 10  µL of CMV B8 or 
A2 specific dextramers (HLA-B*0801/QIKVRVDMV/
PE and HLA-A*0201/NLPMVATV/PE) were added to 
the tube with 1  ×  106 cells. As a negative control HIV 
B8 or A2 specific dextramers (HLA-B*0801/DIYKRWII/
PE and HLA-A*0201/SLYNTVATL/PE) were added to a 
second tube. The cells were incubated at RT in the dark 
for 10 min and then centrifuged as previously. The cells 
were re-suspended in 50 µL wash buffer and 5 µL of the 
following antibodies were added to three of the tubes 
(one tube was used as an unstained control), antihu-
man-CD8-APC (clone SK1, Biolegend, San Diego, CA, 
USA), antihuman-CD4-FITC (clone OKT4, Biolegend), 
antihuman-CD14-FITC (clone HCD14, Biolegend) and 
antihuman-CD19-FITC (clone HIB19, Biolegend), and 
incubated on ice in the dark for 20 min. 2 mL wash buffer 
was added and the cells centrifuged as previously, and the 
wash step repeated. The tubes with 167,000 cells were 
re-suspended in 200  µL wash buffer and the tube with 
1 ×  106 cells were re-suspended in 400  µL wash buffer 
and kept on ice in the dark until analyzed on an Accuri 
C6 flow cytometer. The gating procedure is described in 
Additional file  2: Figure S2. This exact same procedure 
was performed on the cells that were harvested at day 13 
after being stimulated with CMV peptide at day 1.
ELISpot
The functional T cell response against B8 and A2 spe-
cific CMV peptides was tested in an IFN-γ enzyme linked 
immunospot (ELISpotPRO, Mabtech, Nacka Strand, Swe-
den) assay. The cells that were included at day 0 were 
rested for 24  h before 200  µL of the cell solution was 
added to six ELISpot wells, 4 × 105 per well. One tripli-
cate was stimulated directly with a final concentration of 
1 µg/mL of a B8 or A2 specific CMV peptide, while the 
other triplicate was left untreated in medium only. After 
24 h of incubation at 37  °C, the ELISpot assay was per-
formed according to the manufacturer’s protocol. Spots 
were developed for 10 min, and after being washed and 
left to dry for 24 h, the wells were scanned by a Cellular 
Technology limited ELISpot counter and counted on the 
computer. The untreated cell spot count was subtracted 
from the stimulated cells. As positive controls confirm-
ing the viability of cells used in ex vivo ELISpot, activat-
ing anti-CD3 antibodies (clone CD3-2, mouse IgG2a, 
Mabtech) or phytohemagglutinin (PHA, Sigma-Aldrich) 
were used. These mitogenic stimuli generally resulted 
in spots too numerous to count. As negative controls, 
DMSO were added to control wells at the same con-
centration used for dissolving the CMV peptides. The 
same ELISpot procedure was performed on the in vitro 
expanded cells that were harvested at day 13, except 
the amount of cells added to each well was decreased 
to 5 × 104. For cutoff limits we used the guidelines sug-
gested by Chudley et  al. [30] as follows: ELISpot data 
were first processed by expressing each well as spot form-
ing units (SFU) per million PBMC, followed by subtract-
ing the mean spot number of unstimulated cells from the 
stimulated cells. A positive response was acknowledged 
when the mean blank subtracted spot number of CMV 
stimulated cells exceeded 20 SFU per million PBMC for 
ex vivo ELISpot and 500 SFU per million PBMC for ELIS-
pot post in vitro stimulation. The cutoffs always exceeded 
the mean of negative controls by at least two standard 
deviations. The actual presence of IFN-γ producing T 
cells in the ELISpot assays were confirmed by detection 
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of IFN-γ by ELISA (see below) in supernatants of PBMCs 
(n  =  3) stimulated with CMV peptides in parallel with 
ELISpot.
Degranulation assay on stimulated PBMC
From the in  vitro expanded cells harvested at day 
13, 150 µL (300,000 cells) and 50 µL of fresh medium was 
added to four cell tubes. 1 µL of 200× Monensin (Biole-
gend) was added to each tube, while CMV peptide at a 
final concentration of 1 µg/mL was added to tube 1 and 
2. 2  µL of antihuman-CD107a-FITC (clone H4A3, Bio-
legend) was added to tube 1 and 3, while 2 µL of FITC-
conjugated isotype control (BD Biosciences) was added 
to tube 2 and 4. The tubes were incubated at 37  °C for 
4 h. Next, 2 mL wash buffer was added to each tube, cells 
were centrifuged at 400×g for 5  min and re-suspended 
in 100 µL wash buffer. 5 µL of antihuman-CD8-APC was 
added to tube 1 and 3, and the cells were incubated on 
ice in the dark for 15 min. The wash step above was then 
repeated before the cells was re-suspended in 300 µL of 
wash buffer and kept on ice in the dark until analyzed on 
an Accuri C6 flow cytometer, essentially as described in 
[31].
Interferon‑γ ELISA
Serum levels of IFN-γ in a subset of AAD patients 
(n  =  18) and controls (n  =  11) were determined using 
a sandwich ELISA kit from Biolegend; Human IFN-γ 
ELISA MAX™ Deluxe, exactly as described by the manu-
facturer. This ELISA assay was also used for the defection 
of IFN-γ in cell-culture supernatants of CMV peptide 
stimulated cells, to confirm the presence of IFN-γ pro-
ducing T cells in the ELISpot assays.
Statistics
Statistical differences between patients and controls 
were calculated using non-parametric Mann–Whitney 
U test or Fisher’s exact test. For all statistical operations, 
P  <  0.05 was considered significant. All tests were per-
formed with GraphPad Prism v5.02.
Results
Antibodies to cytomegalovirus in AAD patients 
and healthy controls
We measured the frequencies and levels of IgG and IgM 
CMV antibodies in 95 AAD patients (mean age 40.1, 
range 17–82) and 49 healthy controls (mean age 42.0, 
range 20–67). 71.6 % of the patients had CMV IgG anti-
bodies (mean age 41.6), while for the healthy controls this 
number was lower at 61.2  % (mean age 42.8) (Fig.  1a). 
3.2 % of the patients (mean age 34.7) had CMV IgM anti-
bodies compared to 4.1 % for the healthy controls (mean 
age 28.5) (Fig. 1b). The differences in frequencies of CMV 
antibodies between patients and controls were not sig-
nificantly different for either IgG or IgM (P =  0.26 and 
P =  1.0, respectively). The levels of CMV IgG are com-
pared between patients and controls and shown in Addi-
tional file 3: Figure S3, although no significant differences 
were found (P = 0.53).
Frequencies of CMV‑specific CD8+ T cells
After having collected a cohort of patients and controls 
that had IgG antibodies to CMV and were either HLA-
A2 (patients n = 6, controls n = 6) or HLA-B8 (patients 
n = 9, controls n = 10) positive, we wanted to investigate 
whether there were any differences in levels of CMV-spe-
cific CD8+ T cells in PBMC between the two groups. To 
this end, we used HLA-multimer technology to calculate 
the percentage of CMV-specific CD8+ T cells in patients 
and controls. No significant differences were found; 
either in PBMCs stained with HLA-dextramers ex vivo or 
in PBMCs stimulated and expanded in vitro (Fig. 2a). We 
also compared ex  vivo and in  vitro stimulated frequen-
cies of CMV-specific CD8+ T cells with regard to HLA 
types, but no significant differences were found between 
patients and controls carrying either the AAD associated 
HLA-B8 subtype (Fig. 2b) or the common HLA-A2 sub-
type (Fig. 2c).
Production of IFN‑γ after stimulation with CMV peptides
PBMCs from HLA-typed AAD patients and controls 
were stimulated with CMV peptides identical to the ones 
loaded onto the HLA dextramer reagents (restricted to 
either HLA-A2 or HLA-B8) and the resulting IFN-γ pro-
duction was detected in an ELISpot assay. The assay’s 
capability to specifically detect IFN-γ was confirmed by 
ELISA analysis of IFN-γ in supernatants from PBMC cul-
tures stimulated with CMV peptides in parallel to ex vivo 
ELISpot (n = 3). Mean (SD) levels were 453 (± 115) SFU/
million PBMC for ELISpot and 1976 (±  110) pg/mL 
for ELISA, respectively. Similar to the HLA dextramer 
staining, ELISpot assays were performed both ex  vivo 
and after in  vitro stimulation and expansion. However, 
although mean IFN-γ SFU levels were slightly higher 
among the healthy controls, there were no significant dif-
ferences between AAD patients and controls (Fig.  3a). 
Furthermore, no significant differences in the levels 
of IFN-γ production were detected in HLA-B8 posi-
tive (Fig.  3b) or HLA-A2 positive patients and controls 
(Fig. 3c).
Cytolytic granule exocytosis in CMV‑specific CD8+ T cells
In a limited number of patients (n  =  7) and controls 
(n = 10) the levels of degranulation after in vitro stimula-
tion of PBMC were measured. To this end we measured 
the frequencies of CD107a positive CD8 cells after CMV 
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peptide re-stimulation. Again, no significant differences 
could be found between AAD patients and healthy con-
trols (Fig. 4a). Among the HLA-B8 individuals, the mean 
frequency of CD107a positive CD8+ T cells were higher 
among healthy controls than in AAD patients, but as 
the number of patients were low (n =  3) the difference 
was not significant (Fig.  4b). When comparing patients 
and controls with the HLA-A2 type, the frequencies of 
CD107a positive T cells in response to CMV stimula-
tion were highly similar (Fig.  4c). Finally, we also com-
pared the levels of mean fluorescence intensity (MFI) of 
CD107a staining of patient and control cells, but no sta-
tistical differences were found (P = 0.62, Additional file 4: 
Figure S4).
AAD patients have decreased levels of circulating CD8+ T 
cells
While investigating the ex vivo frequencies of HLA-dex-
tramer positive CMV-specific T cells, we noticed that 
the AAD patients (n  =  15) had decreased numbers of 
CD8+ T cells among their PBMCs compared to healthy 
controls (n  =  16) (mean percent CD8+ T cells of total 
PBMC ± SD: 13.8 ± 4.5 vs 21.0 ± 7.1) (Fig. 5). This dif-
ference was highly significant (P = 0.005).
Primary and reactivating CMV infections in individual AAD 
patients
For 15 of the selected patients serum samples taken at 
various time points in the last 15 years were available, and 
Fig. 1 CMV IgG and IgM antibody levels. Platelia immunoassay was used to determine the frequencies of IgG (a), and IgM (b) antibodies to 
cytomegalovirus in serum/plasma samples from AAD patients (n = 95, mean age 40.1) and healthy controls (n = 49, mean age 42). The results are 
shown as percentage positive and negative subjects for each antibody. There were no significant differences in the frequencies of positive anti-CMV 
IgG or IgM between patients and controls as calculated by Fishers’ exact test
Fig. 2 Ex vivo and in vitro stimulated (IVS) frequencies of CMV specific CD8+ T cells in AAD patients and controls. Immudex CMV dextramers were 
used to stain PBMC directly (ex vivo), or after the cells were stimulated with HLA-restricted CMV peptide (1 µg/mL) and expanded for 13 days (in 
vitro stimulated), for HLA-A2 or HLA-B8 CMV specific CD8+ T cells. All samples were analyzed on an Accuri C6 flow cytometer. Results are expressed 
as percentage of CD8+ T cells staining positive for CMV dextramers in a patients and controls. The same data are also shown grouped into HLA-B8 
(b) and HLA-A2 (c) positive patients (b n = ex v. 9, IVS 6, c n = ex v. 6, IVS 4) and controls (b n = ex v. 10, IVS 9, c n = ex v. 6, IVS 4). Non-parametric 
Mann–Whitney U test was used to test for statistical differences between patients and controls, but none were found. The bars display the mean for 
the whole group
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longitudinal studies of anti-CMV antibodies and inves-
tigation of serological CMV status at the point of AAD 
diagnosis, were therefore possible. One patient, originally 
diagnosed with AAD in 2000 and with no other auto-
immune co-morbidities, displayed a peculiar serologi-
cal pattern. From 2000 through 2012 the anti-CMV IgG 
levels remained constantly positive. However, anti-CMV 
IgM antibodies were fluctuating (negative in 2000, posi-
tive in 2006–2007, negative in 2008, Fig. 6a), suggesting 
reactivating CMV infection from latency. This patient, 
who was HLA-B8 positive, had very few CMV-specific 
HLA-dextramer positive CD8+ T cells (less than 0.1 %). 
In a former study, we noticed that isolated CD4+ T cells 
from the patient in question displayed strongly elevated 
mRNA levels of the IFN-regulated genes Ubiquitin Spe-
cific Peptidase 18 (USP18), Eukaryotic translation Ini-
tiation Factor 2-Alpha Kinase 2 (EIF2AK2) and C-X-C 
motif chemokine 10 (CXCL10) compared to other AAD 
patients and healthy controls [32], indicating an IFN sig-
nature in her peripheral blood cells (illustrated here in 
Fig.  6b). Furthermore, the daughter of this patient (also 
HLA-B8 positive) developed AAD in 2012 and, despite of 
being anti-CMV IgG positive, had no detectable CMV-
specific HLA dextramer positive cells. As expected, both 
mother and daughter had very low numbers of IFN-γ 
producing cells after CMV peptide stimulation (38 and 
Fig. 3 Ex vivo and in vitro stimulated (IVS) levels of CMV-specific IFN-γ producing T cells in AAD patients and controls. IFN-γ ELISpot was used to 
determine the amount of CMV-specific T cells in PBMC from HLA-A2 or HLA-B8 patients or healthy controls stimulated with HLA-restricted CMV 
peptide (1 µg/mL) for 24 h (ex vivo) or expanded for 13 days, and then then re-stimulated with CMV peptide for 24 h (in vitro stimulated). The results 
are displayed as means of triplicates of spot forming units (SFUs) per 1 × 106 PBMCs (a). The same data are also shown grouped into HLA-B8 (b) 
and HLA-A2 (c) positive patients (b n = ex v. 9, IVS 8, c n = ex v. 6, IVS 4) and controls (b n = ex v. 10, IVS 10, c n = ex v. 6, IVS 4). Non-parametric 
Mann–Whitney U test was used to test for statistical differences between patients and controls, but none were found. The bars display the mean for 
the whole group
Fig. 4 Levels of degranulating CMV-specific CD8+ T cells in AAD patient and control cells. PBMC from AAD patients and healthy controls were 
stimulated with HLA-specific CMV peptide (1 µg/mL) and expanded for 13 days, before being re-stimulated with CMV peptide and stained with 
anti-human CD107a for 4 h. The cells were also stained with anti-human CD8 before being analyzed on an Accuri C6 flow cytometer. Results are 
expressed as percentage of CD8+ T cells positive for CD107a in patients and controls (a). The same data are also shown grouped into HLA-B8 (b) 
and HLA-A2 (c) positive patients (b n = 3, c n = 4) and controls (b n = 7, c n = 3). Non-parametric Mann–Whitney U test was used to test for statis-
tical differences between patients and controls, but none were found. The bars display the mean for the whole group
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30 SFU/million PBMC, respectively). After in vitro stim-
ulation, the CMV specific cells of the mother could be 
expanded and reached a very high percentage (85.1  %) 
of HLA dextramer positive cells. However, the frequency 
of IFN-γ producing cells were still relatively low at 5927 
SFU/million cells, given the high frequency of dextramer 
positive cells. The CMV specific cells of the daughter 
could not be expanded after in vitro stimulation. The cells 
of both the mother and daughter responded vigorously to 
anti-CD3 stimulation, however, excluding poor viability 
as an explanation for the observed results.
Two patients were positive for anti-CMV IgM at the 
time of AAD diagnosis (one of them also positive for 
IgG), suggesting primary CMV infections as a precipi-
tating factor for adrenal insufficiency in these patients. 
One additional patient became anti-CMV IgM positive 
2 months after AAD diagnosis, with subsequent serocon-
version to positive anti-CMV IgG and negative anti-CMV 
IgM 1 year later. These results are summarized in Table 1.
Serum IFN-γ levels were determined in a subset of 
patients (n = 18) and controls (n = 11), including all sam-
ples positive for anti-CMV IgM antibodies. No statistical 
differences were found between patients and controls 
(Fig.  7a), although individual patients had considerable 
elevated IFN-γ levels. However, when comparing the 
serum IFN-γ levels in patients with IgM antibodies to 
the patients without IgM antibodies, a significant differ-
ence was found (P = 0.035, Fig. 7b). Notably, the patient 
described in Fig.  6 with signs of CMV reactivation and 
an IFN signature in her peripheral blood, were among the 
patients with highest serum levels of IFN-γ (254 pg/mL).
Discussion
It has been suggested that virus infections may pro-
voke AAD in genetically susceptible individuals [33, 34]. 
Direct destruction of adrenocortical cells by virus infec-
tion, immune mediated destruction by cross-reacting 
T cells or non-specific enhancement of antigen presen-
tation has been suggested to be the underlying patho-
genic mechanisms [35]. CMV infection is one of the 
most common viral infections throughout the world and 
has been associated with a number of autoimmune dis-
eases, including systemic lupus erythematosus (SLE), 
T1D, vasculitis and Sjögren’s syndrome [16, 21, 36, 37]. 
Even though a healthy immune system controls CMV 
infection, the virus can never be eliminated by immune 
effector mechanisms or antiviral drugs. Thus, CMV 
Fig. 5 Levels of circulating CD8+ T cells are decreased in AAD 
patients. Flow cytometry was used to calculate the frequencies of 
circulating CD8+ T cells in PBMC from AAD patients (n = 15) and 
healthy controls (n = 16). Non-parametric Mann–Whitney U test was 
used to test for statistical differences between patients and controls, 
(*P < 0.05). The bars display the mean for the whole group
Fig. 6 Reactivation of CMV infection and peripheral interferon signature in an AAD patient. Anti-CMV IgG [(left y-axis AU/mL)] and IgM [right y-axis 
(ratio between optical density and cut-off value)] levels are here shown for one individual patient over a 12 year time period (the patient was 
diagnosed with AAD in the year 2000) (a). IgG values are positive for the entire period (all values are above the short stippled line) while two IgM 
measurements are positive (values above the long stippled line) from 2006 to 2007. In b the relative mRNA expression in isolated CD4+ T cells of the 
three selected ISGs, USP18, EIF2AK2 and CXCL10 previously reported in [32] is shown. The red symbols represent the same patient as in (a)
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establishes persistent life-long infections and may reac-
tivate periodically, possibly representing an environ-
mental risk factor for autoimmune diseases. Primary, 
latent and reactivating CMV infections are controlled 
immunologically by a number of molecular and cellular 
effector systems, including CD4+ and CD8+ T cells, NK 
cells, type I and II IFNs [38]. Antibodies targeting CMV 
virion surface antigens are essential in limiting dissemi-
nation of recurrent virus. Individuals infected with CMV 
are left with permanent imprints affecting their cellular 
immune system, in particular among the CD8+ T cells, 
where up to 20 % of circulating cells may be specific for 
CMV epitopes [39, 40]. For the current study, we there-
fore chose to focus on the CD8+ T cell compartment in 
order to assess CMV-specific immunity in AAD patients.
Individuals that have undergone primary CMV infec-
tion usually remain positive for CMV-specific IgG 
antibodies throughout life. The transient presence of 
CMV-specific IgM antibody has long been used as a 
diagnostic marker for primary CMV infection, but IgM 
can also be present during viral reactivation or reinfec-
tion [41]. In the current study, we initially determined 
and compared the frequencies of anti-CMV IgG and IgM 
antibodies in a relatively large cohort of AAD patients 
and age-matched healthy controls. Although frequencies 
of anti-CMV IgG antibodies were slightly higher among 
patients compared to controls, the difference was not 
statistically significant. Similarly, when comparing the 
levels of anti-CMV antibodies, no differences were found 
between patients and controls. Still, in related studies of 
other autoimmune disorders and their association to viral 
infections (e.g. multiple sclerosis (MS) and Epstein–Barr 
virus, or SLE and CMV), a higher number of sera (>100) 
were needed to establish a statistical significant relation-
ship between seropositivity and autoimmune disease 
[42, 43]. Therefore, a follow-up study with a substantially 
increased number of AAD patient and control sera could 
still reveal possible associations between AAD and CMV.
After having identified patients seropositive for anti-
CMV IgG, we went on to assess whether any defects in 
their cellular immunity against CMV could be detected. 
Assuming that a suboptimal control of CMV in AAD 
patients may be reflected in a decreased number of 
CMV-specific CTLs, we have analyzed the frequencies of 
HLA-B8 and –A2 restricted CTLs in patients and healthy 
controls using HLA-dextramers and IFN-γ ELISpot 
Table 1 Summary of patients positive for IgM close to AAD diagnosis
AAD patient number Age at diagnosis CMV serostatus at diagnosis IFN‑γ levels (IgM) (pg/mL)
IgG IgM








3 32 Negative Positive 4.0
Fig. 7 Increased serum IFN-γ levels in patients positive for anti-CMV IgM antibodies. Serum IFN-γ levels were determined in 18 AAD patients and 
11 healthy controls using sandwich ELISA (a). In b serum IFN-γ levels were compared between those patients positive for anti-CMV IgM antibodies 
(n = 6), with those that were negative (n = 12). Non-parametric Mann–Whitney U test was used to test for statistical differences (*P < 0.05). The bars 
display the mean for the whole group
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assays. T cell responses were investigated both ex  vivo 
and after in  vitro stimulation in order to include both 
effector and central memory T cells. The ex vivo analysis 
clearly demonstrates that the frequency of CMV-specific 
CD8+ T cells in AAD patients are within the range nor-
mally observed in otherwise healthy virus carriers. Simi-
larly, no differences could be detected in the frequencies 
of CMV-specific CD8+ T cells, or in their capacity to 
degranulate upon antigen stimulation after in vitro stim-
ulation and expansion. Overall, our data therefore do not 
support any general defects in AAD patients’ effector of 
memory CTL response to CMV. Still, this is an impor-
tant finding since it indicates that the treatment regime 
for AAD, oral glucocorticoid supplementation therapy, 
does not have a significant functional effect on the in vivo 
expansion or the IFN-γ production profile of CMV-spe-
cific T cells.
Since HLA-B8 is among the strongest predisposing 
genetic factors associated with AAD and a number of 
related autoimmune diseases [28, 44, 45], we were par-
ticularly interested in T cell responses restricted by this 
allele. A suspected consequence of such genetic associa-
tions to autoimmune diseases is perhaps the propensity 
of the allele in question to present certain self-peptides 
[46]. Indeed, a certain peptide of 21-hydroxylase (21OH), 
the major antigen in AAD, has been identified as being 
presented by HLA-B8 to autoreactive CD8+ T cells from 
AAD patients [5, 6]. However, these alleles may also be 
involved in gene-environment interactions, presenting 
peptides from viral or infectious agents in an aberrant 
or deficient manner. We found no differences between 
HLA-B8 positive AAD patients and controls in frequen-
cies of ex vivo or in vitro expanded CMV-specific T cells, 
or in their abilities to produce IFN-γ or degranulate. A 
similar picture emerged when comparing AAD patients 
and healthy controls carrying the common MHC class I 
variant HLA-A2. We did notice that HLA-A2 restricted 
responses in general tended to be stronger than HLA-
B8 restricted responses. This pattern was evident both 
ex  vivo and in in  vitro expanded cells for both AAD 
patients and controls. In fact, when all cellular sam-
ples were grouped according to HLA type regardless of 
disease status, HLA-A2 restricted responses were sig-
nificantly stronger than HLA-B8 restricted responses 
(data not shown). This must be interpreted with caution 
since there are several immunodominant CMV-specific 
epitopes that are presented by both HLA-A2 and HLA-
B8 [47, 48], and in the current study we only had the 
opportunity to assess one epitope per HLA type. How-
ever, a similar scenario has been described for HLA-B8 
restricted T cells from healthy donors and their relative 
insufficiency to lyse EBV infected B cells, compared to 
T cells restricted to other HLA types [49]. HLA-B8 is 
also part of the ancestral MHC haplotype 8.1 (consisting 
of HLA-A1, -B8, -C7, -DR3 and -DQ2), which has been 
described to affect early stages of lymphocyte activation 
and modulate cytokine production [45]. In particular, 
IFN-γ production is reduced in carriers of the 8.1 haplo-
type [50].
When analyzing the HLA-dextramer data, we noticed 
that the AAD patients had significantly fewer circulating 
CD8+ T cells among their PBMCs than healthy controls. 
To our knowledge this has never been reported for AAD 
previously, but has been recognized for many years as a 
general feature of several autoimmune diseases (reviewed 
in [51]). The deficiency in CD8+ T cells is probably genet-
ically determined since it also occurs in healthy family 
members of patients with autoimmune diseases [52]. The 
significance of this general phenomenon is currently not 
known, but redistribution and sequestration of the CD8+ 
T cells to the target organ is one of the suggested possi-
bilities [53]. Another hypothesis is that the deficiency of 
CD8+ T cells impairs the control of EBV infection, result-
ing in clonal expansion of autoreactive EBV infected B 
cells in the target organ followed by infiltration of autore-
active T cells and extensive tissue damage [51].
Even though AAD patients in general had normal cellu-
lar and humoral immune responses to CMV, some devia-
tions were found in individual patients. Three patients 
were anti-CMV IgM positive close to the point of AAD 
diagnosis. Two of them were also IgG negative suggest-
ing that CMV primary infection were involved as a trig-
gering or precipitating factor. This complements a recent 
case report describing a young female developing AAD 
shortly after undergoing verified CMV infectious mono-
nucleosis [19]. Another patient initially only positive for 
IgG became IgM positive for a period of 2 years, suggest-
ing reactivating or secondary CMV infection. Strikingly, 
this patient also had very few circulating CMV-specific 
T cells and consequently very poor IFN-γ production in 
response to CMV peptides. The patient also had an IFN 
signature in her peripheral blood cells, and very high 
serum levels of IFN-γ. We speculate that the latter may 
be a consequence of persistent CMV infection since the 
CMV virion associated factors recognized by host cells as 
foreign pathogen-associated molecular patterns (PAMPs) 
activate IRF3, NFκB and an overall transcriptional profile 
similar to that observed following IFN treatment [54]. 
These speculations were also supported by the fact that 
this patient, and also most of the other AAD patients with 
IgM antibodies against CMV, had very high serum levels 
of IFN-γ. Such high systemic IFN-γ levels have previously 
been described to reflect primary CMV infection [55]. 
Finally, the daughter of the patient mentioned above also 
developed AAD, and displayed the same anti-CMV cellu-
lar patterns: low levels of CMV-specific HLA-dextramer 
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positive cells, and very low IFN-γ production after stimu-
lation with CMV peptide, in spite of being anti-CMV IgG 
positive. All in all, the findings in this mother and daugh-
ter suggest an inheritable immunological phenotype with 
susceptibility of developing AAD and decreased cellular 
immunity against CMV. Still, it must also be mentioned 
that lacking CD8+ T cell responses to CMV peptides 
were also observed among the controls, even in the pres-
ence of positive anti-CMV IgG, as other have reported 
previously [56].
Both CD4+ and CD8+ T cells, NK cells and antibodies 
against surface antigens play a crucial role in the immune 
defense against CMV, preventing the development of 
CMV disease in the immunocompetent host [38]. Any 
patient-specific deficiencies in controlling CMV infec-
tion may therefore be inherent to any of these cellular 
subsets, and not just to CD8+ T cells that were the main 
focus of the present study. Furthermore, because the 
experimental approaches used to investigate CTLs in 
our current investigation do not include subset-specific 
analysis of CD8+ T cells, we cannot exclude that such dif-
ferences might have escaped detection. In patients with 
MS, a deficiency in CD8+ effector memory cells has been 
described as a feature that may underlie poor control of 
EBV infection [57]. A more in depth analysis of the cytol-
ytic capabilities of CMV specific CD8+ T cells is also war-
ranted, since the degranulation assay we have performed 
in the current study only included a limited number of 
patients and controls and lacked a proper positive control 
such as staphylococcal enterotoxin B (SEB).
In order to fully investigate CMV immunity in AAD 
patients, CD4+ T cell immunity should also be assessed 
in future studies. The importance of such studies is under-
lined by the fact that the strongest genetic factors asso-
ciated with the risk of developing AAD are certain HLA 
class II alleles [28, 29]. In particular, it would be of high 
interest to analyze the presence of CD4+CD28− T cells, 
which have been implicated in both autoimmune diseases 
like rheumatoid arthritis, MS and Graves’ disease [58–60], 
but also specifically in relation to CMV infection [61].
Conclusion
We could not find evidence that CMV infection is a 
major player in the pathogenesis of AAD. In general, both 
humoral and CD8+ T cell mediated immunity to CMV 
are normal in patients with AAD. However, as AAD is 
a multifactorial disorder we find it likely that common 
infections with persistent viral agents such as CMV may 
contribute as a triggering or precipitating factor in indi-
vidual patients. The genetic susceptibility to develop 
autoimmune diseases such as AAD may also go hand in 
hand with slightly less robust immunity to common path-
ogens such as CMV and other herpesviruses.
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